ArticleChildren (Basel, Switzerland)2025
Comparison of Clinical Outcomes Between Calfactant and Poractant-Alfa in Preterm Infants with Respiratory Distress Syndrome.
Article in Children (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study compares short- and mid-term morbidity and mortality outcomes in preterm infants treated with the natural surfactants poractant alfa and calfactant, to assess differences in their clinical efficacy and safety profiles.
methodsIn this prospective cohort study, preterm infants (25
resultsThe study included 215 preterm infants (137 in the poractant alfa group; 78 in the calfactant group). Use of less invasive surfactant administration (LISA) and INSURE techniques was significantly higher in the poractant alfa group (32.8% vs. 10.3%;
conclusionsCompared with calfactant, poractant alfa offers practical advantages-such as a higher initial dose, lower cost, and reduced need for a second repeat dose-while yielding comparable short- and mid-term morbidity and mortality outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.